SCHEMBL24065737

SCHEMBL24065737

COC(=O)c1cc([N+](=O)[O-])c(C(F)(F)F)cc1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 1/20 0.45
FGFR1 P11362 1/20 0.45
PDGFRA P16234 1/20 0.45
FLT1 P17948 1/20 0.45
FGFR3 P22607 1/20 0.45
KDR P35968 1/20 0.45
AR P10275 7/20 0.44
CYP3A4 P08684 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 2/20 0.44
CES2 O00748 1/20 0.44
ABCB11 O95342 1/20 0.44
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
GLA P06280 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
CYP2C9 P11712 1/20 0.44
ALOX15 P16050 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30250301 0.90 CFTR (0.49) FLT1KDRARCYP3A4SMN1; SMN2
SCHEMBL2239932 0.89 PDGFRB (0.45) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL16647610 0.85 ALDH1A1 (0.51) ARSMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL2390749 0.84 CFTR (0.62) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL1301766 0.84 CHEK1 (0.46) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2247382 0.83 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2895340 0.83 PDGFRB (0.50) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2035638 0.83 CFTR (0.43) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL2597417 0.83 CFTR (0.43) PDGFRBFGFR1PDGFRAFLT1FGFR3
SCHEMBL22833807 0.83 CFTR (0.43) PDGFRBFGFR1PDGFRAFLT1FGFR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4583867-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE Latigo Biotherapeutics, Inc. (US) 2025-07-16 EP disclosed
CN-119894509-A Sodium channel blocking compounds, derivatives thereof, and methods of use thereof 拉堤果生物医疗股份有限公司 2025-04-25 CN disclosed
CN-115667241-B Trka inhibitors 伊莱利利公司 2024-04-16 CN disclosed
WO-2024054622-A2 SODIUM CHANNEL BLOCKING COMPOUNDS, DERIVATIVES THEREOF, AND METHODS OF THEIR USE LATIGO BIOTHERAPEUTICS, INC. (US) 2024-03-14 WO disclosed
EP-4126842-B1 TRKA INHIBITOR LILLY CO ELI (US) 2023-06-28 EP disclosed
EP-4126842-B1 TRKA INHIBITOR LILLY CO ELI (US) 2023-06-28 EP disclosed
EP-4126842-A1 TRKA INHIBITOR ELI LILLY AND COMPANY (US) 2023-02-08 EP disclosed
CN-115667241-A TrkA inhibitors 伊莱利利公司 2023-01-31 CN disclosed
US-20210371399-A1 TrkA Inhibitor ELI LILLY AND COMPANY 2021-12-02 US disclosed
US-20210371399-A1 TrkA Inhibitor ELI LILLY AND COMPANY 2021-12-02 US disclosed
WO-2021242677-A1 TRKA INHIBITOR ELI LILLY AND COMPANY (US) 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371399-A1 TrkA Inhibitor NGF, NGFR, OPRL1 PDGFRB 106/4885FGFR1 215/4885PDGFRA 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.